The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
- 1 July 1999
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 48 (7) , 935-941
- https://doi.org/10.1016/s0026-0495(99)90232-9
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrationsDiabetologia, 1997
- Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trialDiabetes, 1997
- Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDMDiabetologia, 1997
- Dose-response for glucagonostatic effect of amylin in ratsMetabolism, 1997
- Preliminary report Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptakeMetabolism, 1996
- Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin AnalogueDiabetes Care, 1995
- Glucagon and its Family RevisitedDiabetes Care, 1995
- Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM PatientsDiabetes, 1991
- THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUSThe Lancet, 1975
- Glucagon Physiology and PathophysiologyNew England Journal of Medicine, 1971